EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study

Yi-Long Wu, Hye Ryun Kim, Ross A Soo, Qing Zhou, Hiroaki Akamatsu, Gee-Chen Chang, Chao-Hua Chiu, Hidetoshi Hayashi, Sang-We Kim, Yasushi Goto, Terufumi Kato, Jianying Zhou und 10 weitere

Journal of Thoracic Oncology · 2025

DOI: 10.1016/j.jtho.2025.02.021 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thoracic Oncology, 2025. Verfasst von Yi-Long Wu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical Sciences, Guangzhou…. Hauptthemen laut MEDLINE: Crizotinib, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Lorlatinib, a third-generation anaplastic lymphoma kinase inhibitor, reported significantly longer progression-free survival (PFS) than crizotinib in the phase 3 CROWN trial (NCT03052608) in patients with previously untreated advanced anaplastic lymphoma kinase-positive NSCLC. Efficacy was similar in the Asian subgroup. We present an updated subgroup analysis in Asian patients after five years of follow-up. METHODS: Patients were randomly (1:1) assigned to receive lorlatinib 100 mg once daily (n = 59) or crizotinib 250 mg twice daily (n = 61). This post hoc analysis presents updated investigator-assessed efficacy outcomes, safety, and biomarker analyses. RESULTS: After a median follow-up of 62.4 months for lorlatinib and 55.1 months for crizotinib, median PFS was not reached (NR, 95% confidence interval [CI]: 64.3‒NR) and 9.2 months (95% CI: 7.2‒12.7), respectively (hazard ratio [HR] = 0.22, 95% CI: 0.13‒0.37); the five-year PFS was 63% (95% CI: 49-74) and 7% (95% CI: 2-17). The objective response rate was 81% (95% CI: 69-90) with lorlatinib and 59% (95% CI: 46‒71) with crizotinib. In patients with baseline brain metastases, the intracranial objective response rate was 69% (95% CI: 39‒91) with lorlatinib and 6% (95% CI:

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CrizotinibLung NeoplasmsCarcinoma, Non-Small-Cell LungAnaplastic Lymphoma KinaseLactams, MacrocyclicHumansMaleFemaleAminopyridinesMiddle AgedLactamsAgedAdultFollow-Up StudiesSurvival RateProtein Kinase InhibitorsPyrazoles

Stichwörter der Autor:innen

Anaplastic lymphoma kinaseLorlatinibNon–small cell lung cancerPhase 3Progression-free survival

Substanzen

lorlatinibCrizotinibAminopyridinesLactamsAnaplastic Lymphoma KinaseLactams, MacrocyclicALK protein, humanProtein Kinase InhibitorsPyrazoles

Autor:innen und Institutionen

  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical Sciences, Guangzhou, People's Republic of China. Electronic address: yylwu@live.cn.
  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Haematology-Oncology, National University Cancer Institute Singapore, National University Health System, Singapore, Singapore.
  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical Sciences, Guangzhou, People's Republic of China.
  • Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
  • School of Medicine and Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; I…

Förderung

  • Pfizer

Zitieren

APA

Wu, Y. L., Kim, H. R., Soo, R. A., Zhou, Q., Akamatsu, H., Chang, G. C., Chiu, C. H., Hayashi, H., Kim, S. W., Goto, Y., Kato, T., Zhou, J., Lee, V. H., Nishio, M., Han, B., Kim, D. W., Lu, S., Polli, A., Martini, J. F., …, & Mok, T. (2025). First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2025.02.021

Vancouver

Wu YL, Kim HR, Soo RA, Zhou Q, Akamatsu H, Chang GC, et al. First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study. Journal of Thoracic Oncology. 2025. doi:10.1016/j.jtho.2025.02.021

BibTeX
@article{Wu2025,
  author = {Wu, Yi-Long and Kim, Hye Ryun and Soo, Ross A and Zhou, Qing and Akamatsu, Hiroaki and Chang, Gee-Chen and Chiu, Chao-Hua and Hayashi, Hidetoshi and Kim, Sang-We and Goto, Yasushi and Kato, Terufumi and Zhou, Jianying and Lee, Victor Ho-Fun and Nishio, Makoto and Han, Baohui and Kim, Dong-Wan and Lu, Shun and Polli, Anna and Martini, Jean-François and Toffalorio, Francesca and Wong, Chew Hooi and Mok, Tony},
  title = {First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study},
  journal = {Journal of Thoracic Oncology},
  year = {2025},
  doi = {10.1016/j.jtho.2025.02.021}
}
Kostenlos starten →